These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17199131)

  • 1. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.
    Ruaño G; Goethe JW; Caley C; Woolley S; Holford TR; Kocherla M; Windemuth A; de Leon J
    Mol Psychiatry; 2007 May; 12(5):474-82. PubMed ID: 17199131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
    Houston JP; Kohler J; Bishop JR; Ellingrod VL; Ostbye KM; Zhao F; Conley RR; Poole Hoffmann V; Fijal BA
    J Clin Psychiatry; 2012 Aug; 73(8):1077-86. PubMed ID: 22967772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.
    Smith RC; Rachakonda S; Dwivedi S; Davis JM
    Psychiatry Res; 2012 Oct; 199(3):159-63. PubMed ID: 22475524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.
    Kuzman MR; Medved V; Bozina N; Hotujac L; Sain I; Bilusic H
    Psychiatry Res; 2008 Sep; 160(3):308-15. PubMed ID: 18718676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
    Alméras N; Després JP; Villeneuve J; Demers MF; Roy MA; Cadrin C; Mottard JP; Bouchard RH
    J Clin Psychiatry; 2004 Apr; 65(4):557-64. PubMed ID: 15119921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels.
    Roerig JL; Steffen KJ; Mitchell JE; Crosby RD; Gosnell BA
    J Clin Psychopharmacol; 2008 Feb; 28(1):21-6. PubMed ID: 18204336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.
    Perez-Iglesias R; Crespo-Facorro B; Martinez-Garcia O; Ramirez-Bonilla ML; Alvarez-Jimenez M; Pelayo-Teran JM; Garcia-Unzueta MT; Amado JA; Vazquez-Barquero JL
    Schizophr Res; 2008 Feb; 99(1-3):13-22. PubMed ID: 18053689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.
    Fleischhaker C; Heiser P; Hennighausen K; Herpertz-Dahlmann B; Holtkamp K; Mehler-Wex C; Rauh R; Remschmidt H; Schulz E; Warnke A
    J Neural Transm (Vienna); 2007 Feb; 114(2):273-80. PubMed ID: 17109073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antidepressant effects of risperidone and olanzapine in bipolar disorder.
    McIntyre RS; Mancini DA; Srinivasan J; McCann S; Konarski JZ; Kennedy SH
    Can J Clin Pharmacol; 2004; 11(2):e218-26. PubMed ID: 15520475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
    Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
    Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment.
    Tsai A; Liou YJ; Hong CJ; Wu CL; Tsai SJ; Bai YM
    Neuromolecular Med; 2011 Dec; 13(4):328-33. PubMed ID: 21956459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).
    Gareri P; Cotroneo A; Lacava R; Seminara G; Marigliano N; Loiacono A; De Sarro G
    Arch Gerontol Geriatr Suppl; 2004; (9):207-15. PubMed ID: 15207416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel antipsychotics: comparison of weight gain liabilities.
    Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR
    J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
    Hardy TA; Marquez E; Kryzhanovskaya L; Taylor CC; Cavazzoni P
    J Clin Psychopharmacol; 2006 Aug; 26(4):405-8. PubMed ID: 16855460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
    Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
    Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of second generation antipsychotics on leptin and ghrelin.
    Esen-Danaci A; Sarandöl A; Taneli F; Yurtsever F; Ozlen N
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1434-8. PubMed ID: 18579280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.
    Kinon BJ; Liu-Seifert H; Ahl J; Ahmed S; Baker RW
    Ann N Y Acad Sci; 2004 Dec; 1032():295-6. PubMed ID: 15677433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.
    Vera-Llonch M; Delea TE; Richardson E; Rupnow M; Grogg A; Oster G
    Value Health; 2004; 7(5):569-84. PubMed ID: 15367252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.